Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2018 · 10-Q
Revenue$4.84M$4.84M+44.1% vs Q3 2017 Net Income-$3.19M-$3.19MN/M vs Q3 2017 EPS Diluted-$0.73-$0.73N/M vs Q3 2017 Gross Profit$2,368,000+38.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,158,000N/M Free Cash Flowderived-$2,174,000N/M Margins · derivedGross margin48.9%−1.9 pt vs Q3 2017
Operating margin-66.1%+40.0 pt vs Q3 2017
Net margin-65.8%
ended Dec 31, 2017 · filed Feb 14, 2018 · 45 d after period end